Jessica Breu

Halfway point at May 50K! 💪 The $IMUX team is off to a strong start with 800 km already logged. Let’s keep the momentum going – every step, ride, swim, and roll counts. There is still time to sign up and get active: 👉 themay50k.de @DMSG_BV, @mssocietyuk, @MSIntFederation, @MSIRELAND, #May50K #MSAwareness #MoveForMS #ImmunicInMotion #Immunic

Q1 Update: Setting the Course for 2026 📈 Yesterday, we reported our first quarter 2026 financial results and a corporate update, highlighting continued progress across our clinical development pipeline, the appointment of our new Chief Medical Officer, and a strengthened financial position. 🎥 Our CEO Dr. Daniel Vitt spoke with @Proactive_US about the recent updates and what lies ahead for #Immunic. Watch the full interview here: bit.ly/4dj6Wmy #biotechnology #immunology #IMUX

Today, we reported our first quarter #FinancialResults and a provided a #CorporateUpdate. Key highlights include: 📣 Appointed globally renowned biopharmaceutical executive and #neurology drug developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer 🚀 Continued to execute phase 3 #ENSURE trials of #vidofludimus calcium (#IMU838) in relapsing #MultipleSclerosis (#MS #RMS), with top-line data expected by end of 2026 📈 Raised $200 million in an oversubscribed private placement, with potential for up to an additional $200 million 👉 Get all the details here: bit.ly/3PAkceI #Immunic $IMUX #IMU838 #MSResearch #biotech #healthcare

🧩 Treating symptoms is one piece of the puzzle. Targeting underlying disease biology is another. 🎙️ On the Base to Base Biotech podcast, our CEO Dr. Daniel Vitt joined host Jim Cornall for a wide‑ranging discussion on #Immunic, our focus on neurologic diseases, the science behind our clinical and preclinical programs, and the challenges of developing therapies that aim beyond symptom control. 🎧 Listen to the full episode to hear what lies ahead for Immunic and for the patients we are working to support: bit.ly/48MhVna $IMUX #vidofludimus #IMU838 #neurology #MultipleSclerosis #MS

Tomorrow, the Clinical Trial Supply Forum kicks off in Amsterdam, bringing together experts to exchange perspectives on how clinical supply chains can better support increasingly complex trials. 🌍 Our colleague Kimi Le, Global Head of #ClinicalTrialSupply, will contribute to the program with a case study today, May 12 (12:15-12:45 CEST), sharing perspectives on strategies for clinical supply success and the role of strong sponsor-vendor partnerships. She will also take part in a panel discussion later in the day focused on emerging technologies shaping the future of clinical trial supplies. 🔬 Looking forward to thoughtful discussions and shared learnings over the coming days in Amsterdam. 🇳🇱 @PharmaIQ #Immunic $IMUX

🎗️ We appreciated the opportunity to attend the 12th MSAA Improving Lives Benefit Gala last week and support the important work of the @MSassociation. Being there together with our new medical affairs team reflected the importance of staying closely connected with the #MultipleSclerosis (#MS) community as we move through a meaningful year for #Immunic. 🧡 $IMUX #vidofludimus #IMU838 #RaisingAwareness

Two days of insightful dialogue at #BioEquity Europe 🇪🇺 🤝 Our CEO, Dr. Daniel Vitt, and VP #InvestorRelations & #Communications, Jessica Breu, appreciated the many 1:1 conversations with investors and industry peers – reconnecting with familiar faces and meeting new ones. 🙏 Thank you to @BioCentury, @InformaConnect and @EBDgroup for hosting a great event in #Prague 🇨🇿. We look forward to next year’s edition in #Copenhagen 🇩🇰. $IMUX #Networking #BioEquityEurope #EBDGroup

May 50K is underway and there’s still time to join! The #May50K Challenge is well underway, and it’s great to see so many moves already adding up. Still thinking about joining? There’s plenty of May left. 💙 👉 themay50k.de @DMSG_BV, @mssocietyuk, @MSIntFederation, @MSIRELAND, #MSAwareness #MoveForMS #ImmunicInMotion #Immunic $IMUX

✨ Marking the appointment of Michael A. Panzara, M.D., M.P.H., as our new Chief Medical Officer showcased on the #Nasdaq tower in #NewYorkCity. 🏙️ Thank you, @Nasdaq, for the continued support. And welcome again to the $IMUX team, Mike! #NasdaqListed #Leadership #Immunic

#BioEquity Europe brings together the people and ideas shaping the next phase of #biotech #innovation. 📅 On May 5 and 6, Dr. Daniel Vitt, Chief Executive Officer, and Jessica Breu, Vice President #IR & Communications, will be attending #BioEquityEurope in Prague, Czech Republic 🇨🇿 and look forward to engaging with investors and industry peers - both from Europe and internationally. 👉 Let’s connect! @BioCentury $IMUX #InvestorRelations #Networking

🚶‍♀️ May 50K Challenge for MS! This May, we are joining the #May50K Challenge to support people affected by #MultipleSclerosis (#MS). Whether it’s walking, running, swimming, rolling or simply staying active in your own way, every step counts. 🚴‍♂️ 🏊‍♀️ And we are not doing this alone. We are inviting our colleagues, friends, families, and everyone in our network to join us. Move with us, in your own way, at your own pace, for a shared purpose! 👉 themay50k.de Because progress is built step by step. Let’s move together. 💙 @DMSG_BV, @mssocietyuk, @MSIntFederation, @MSIRELAND, #MSAwareness #MoveForMS #ImmunicInMotion #Immunic $IMUX

📢 #Immunic will participate in key investor and medical conferences this upcoming May, engaging with the scientific and investor communities around advances in neurologic disease research. 💼 May 4 - 6 & 12 - 13 | Bio€quity Europe (#Prague, Czech Republic & virtual) Our CEO Dr. Daniel Vitt and Jessica Breu, VP IR & Communications, will attend and host one‑on‑one investor meetings. 🧠 May 27 - 29 | Consortium of Multiple Sclerosis Centers (#CMSC) Annual Meeting (#Charlotte, NC, USA) Meet members of our management, medical, and preclinical teams at booth 307. Additionally, don't miss our late‑breaking poster and two additional posters, including new analyses from our phase 2 #CALLIPER trial of #vidofludimus calcium in progressive #MultipleSclerosis (#MS, #PMS). 👉 View all details on these conferences and the accepted posters here: bit.ly/3QFTG3M @BioCentury @mscare #MSResearch #Neurology $IMUX #IMU838 #InvestorRelations

🌍 As #WorldImmunizationWeek (Apr 24-30) draws to a close, we also mark the #InternationalDayOfImmunology today, organized by @UISorg and @European Federation of Immunological Societies - EFIS. 🧬 #Immunology helps us understand how body's defence system functions and how its responses might be modulated in a targeted way. This knowledge has enabled #vaccines that have helped protect more than 150 million lives globally over the past five decades. 🛡️ 🧪 At #Immunic, immunology is not an abstract concept,but a core pilar of our science. A deeper understanding of immune mechanisms is an important part of how we explore potential new approaches for immune-mediated diseases such as #MultipleSclerosis (#MS). 🔬 Days like these highlight the importance of continued research to further advance our understanding of the immune system and its role in human health. @WHO #VaccinesWork $IMUX

📢 At an important and transformative stage in #Immunic’s ($IMUX) evolution toward becoming a fully integrated commercial stage entity, we are very pleased to welcome Michael A. Panzara, M.D., M.P.H., as our new Chief Medical Officer. Mike brings over 25 years of drug development expertise in #neurology and proven #leadership in delivering transformational therapies to #MultipleSclerosis (#MS) patients. As a globally renowned biopharmaceutical executive, his depth of experience will be invaluable as we advance #vidofludimus calcium through pivotal development and towards potential regulatory approval and commercialization. Dr. Panzara will lead our development organization, including clinical development, medical affairs, and regulatory affairs, and will be a critical partner to the CEO and the Board of Directors in defining and driving the overall company strategy. 👉Learn all the details here: bit.ly/3QzFitU

🧠 Slowing disability progression in MS remains one of the field’s biggest unmet needs. While currently approved therapies can reduce relapses and inflammatory activity, they fall short in addressing the #neurodegeneration that drives long-term disability, especially in progressive forms of #MultipleSclerosis (#MS, #PMS). In this episode of The Bio Report by @lmgbio, our CEO Dr. Daniel Vitt discusses how #Immunic takes a differentiated approach with #vidofludimus calcium, a once-daily oral drug candidate in phase 3 clinical development, designed to address both #neuroinflammation and neurodegeneration. 🎧 Hear the full discussion: bit.ly/3Qn8Afe #MSResearch #Neuroprotection #DrugDevelopment #IMU838 $IMUX

Did you know? Over the last 50 years, #immunization has helped protect more than 150 million lives worldwide. 🛡️ 🌍 #WorldImmunizationWeek (April 24-30) highlights the role of scientific research and evidence‑based standards for #vaccines. As a science‑driven company, we support this focus. 💉 Learn more about the science behind vaccines: 👉 bit.ly/4287A1f @WHO #VaccinesWork

Thank you, #AAN2026 👏 As the @American Academy of Neurology Annual Meeting wraps up, we are thankful for the many great conversations with both new and familiar faces across the #MultipleSclerosis (#MS) community. It was a pleasure to have members of our newly expanded medical affairs team, alongside our medical and preclinical colleagues, on site in #Chicago, engaging in discussions around our development progress with #vidofludimus calcium and its potential neuroprotective approach for MS. 🧠 Thank you to everyone who connected with us throughout this past week. #MSResearch #Neurology #IMU838 $IMUX

Most MS drugs control relapses—but don’t stop the neurodegeneration driving long-term disability. Daniel Vitt, CEO of @ImmunicInc discusses how his company’s experimental once-daily oral therapy targets both inflammation and neuronal damage. thebioreport.podbean.com/e/slowing-disa…

🎗️ We support #MSAwarenessWeek and the MS Society’s #MSThinkAgain campaign. 🧡 🧠 #MultipleSclerosis (#MS) looks different for every affected individual. Assumptions about MS can make living with the condition harder than it needs to be. This powerful video by the @mssocietyuk challenges common misconceptions and encourages all of us to think again! 👉 bit.ly/3Qjqr6Q 💬 Join the conversation and help raise awareness! #Immunic $IMUX #neurology

Advancing new perspectives in multiple sclerosis research - joining the conversation at #AAN2026. 🧠 Immunic will be attending the @AmericanAcademyofNeurology (#AAN) Annual Meeting in #Chicago taking place April 18-22. Members of our medical and preclinical teams will be on site and are looking forward to discussions around our work on #vidofludimus calcium, including its potential neuroprotective effects for #MultipleSclerosis (#MS) treatment. 💡 We look forward to sharing new findings from our phase 2 #CALLIPER trial in progressive MS (#PMS), and what’s ahead as we approach the read-out of our phase 3 #ENSURE trials in relapsing MS (#RMS). 📍 Visit us at booth 3830 Let’s connect, discuss data, and share perspectives on where MS research may be headed. Looking forward to great conversations at AAN! @AANmember $IMUX #neurology #IMU838